Corporate actions12 Oct 2026 · Mon
JUBLPHARMAJubilant Pharmova
Jubilant Pharmova approves ₹800 crore of debentures and seeks a ₹2,500 crore debt limit
Jubilant Pharmova's board approved a private placement of non-convertible debentures worth up to ₹800 crore and will seek shareholder approval for a ₹2,500 crore debt limit.
Price, Monday's close₹965.00▲ 3.55%
Last 5 days
52-week low ₹786.0552-week high ₹1,184.80
- Sector
- Pharmaceuticals
What happened
- Jubilant Pharmova's board approved a private placement of 80,000 non-convertible debentures of ₹1 lakh each, raising up to ₹800 crore, according to Sahi and DSIJ.
- DSIJ said the debentures will be rated, listed on BSE and have a tenure of up to five years, with the coupon set through bidding. DSIJ said the company has not disclosed what the money will be used for.
- The company will also seek shareholder approval to issue up to ₹2,500 crore of debt securities over 12 months. DSIJ said this will be by postal ballot.
- DSIJ put the company's consolidated borrowings at ₹3,219.5 crore at the end of March 2026.
- The shares closed at ₹965, up 3.55%.
Why it matters
Good to know: A non-convertible debenture is a loan that cannot be turned into shares. In a private placement it is sold to a limited set of institutions rather than offered to the public.
Key facts
- Debenture issue
- Up to ₹800 crore (80,000 of ₹1 lakh each)
- Tenure
- Up to five years
- Debt limit sought
- ₹2,500 crore over 12 months
Read the source
This is a summary of public news about Jubilant Pharmova, for information only. It is not a recommendation to buy, sell or hold JUBLPHARMA.